Stock Price & Analysis

Based on the provided data and recent market activity, here's my analysis for COR stock:

Technical Analysis

The stock is showing strong bullish momentum with an RSI of 71.10, indicating slightly overbought conditions. The stock is trading above all major moving averages (5-day: $244.58, 10-day: $241.07, 20-day: $234.29), suggesting a strong uptrend.

Recent Performance COR closed at $247.94 on January 23, 2025, with a modest gain of +0.40% during regular trading hours. The stock traded between $246.02 and $249.09, with relatively healthy volume of 1.17 million shares.

Analyst Sentiment Recent analyst actions show mixed but generally positive sentiment:

• Wells Fargo: Hold rating with $237 PT (Dec 13, 2024)
• Evercore ISI: Buy rating with $285 PT (Nov 7, 2024)
• Barclays: Buy rating with $290 PT (Nov 7, 2024)
• UBS: Strong Buy rating with $285 PT (Nov 7, 2024)
• Baird: Buy rating with $292 PT (Nov 7, 2024)

Business Fundamentals Cencora is showing strong business momentum, particularly in:

• Core pharmaceutical distribution business performance
• Growth in specialty products including GLP-1 drugs
• Strong financial health with expected earnings growth of 8.9% for fiscal 2025

Recommendation SELL. Despite positive analyst sentiment and strong fundamentals, the stock is showing overbought conditions with RSI above 70. The current price of $247.94 is approaching several analysts' price targets, suggesting limited upside potential in the near term. Additionally, the stock has seen significant gains over the past year and may be due for a pullback.

Based on the provided data and current market conditions, here's the price prediction for COR stock in 2025:

Cencora (COR) stock is expected to reach $275-280 by end of 2025, driven by strong fundamentals and positive market sentiment. The company's focus on pharmaceutical distribution and healthcare solutions, combined with its strategic capital deployment and efficiency initiatives, supports this bullish outlook. Recent technical indicators show RSI at 71.10 suggesting slight overbought conditions but still maintaining upward momentum.

The stock has demonstrated resilience with current trading at $249, showing a positive trend from its Fibonacci support levels of $235.34. The company's long-term earnings growth expectation of 10.4% and consistent track record of beating earnings estimates by an average of 7% further reinforces this price target.

The S1 support level for COR Stock is $235.69 ,The R1 resistant level for COR Stock is $247.6.

As of the end of day on 2025-01-24, the price of COR Stock was $248.09.

The target price for COR Stock according to analyst rating is 274.91, with the highest price target at 302.00 and the lowest at 237.00. Analysts have a Moderate Buy rating on COR Stock overall.

The market cap of COR is $48.2B.

Based on the provided data and recent market analysis, here's a comprehensive evaluation of COR's valuation:

Current Market Position COR is currently trading at $247.94, showing a modest gain of +0.40% in the regular market session on January 23, 2025. The stock has been maintaining a relatively stable trading range between $246.02 and $249.09.

Valuation Metrics Analysis

• P/E ratio has fluctuated between 24.44x to 29.87x in recent quarters, indicating a moderate premium compared to historical levels
• EV/EBITDA ratio has improved from 13.15x to 11x, suggesting better operational efficiency
• Price-to-Sales ratio remains attractive at 0.15-0.18x, reflecting efficient capital utilization
• Price-to-Book ratio has increased significantly from 44.73x to 67.93x, which could be a concern

Business Performance According to recent analysis, COR demonstrates strong business economics with:

• Exceptionally high capital turns of >25x versus post-tax operating margins of <4%
• Productivity gains with significant profit per employee improvements
• Low reinvestment requirements maintaining current earnings levels
• Strong free cash flow conversion exceeding reported earnings

Analyst Perspectives Recent analyst ratings show mixed but generally positive sentiment:

• Wells Fargo maintained Hold rating with PT $237 (December 2024)
• Evercore ISI Group and Barclays maintain Buy ratings with PTs of $285 and $290 respectively
• UBS raised PT to $285 with a Strong Buy rating
• Baird maintains Buy rating with $292 PT

Conclusion COR appears to be fairly valued to slightly overvalued at current levels. While the company demonstrates strong business fundamentals and competitive advantages, the current valuation multiples and recent analyst price targets suggest limited upside potential from current levels. The stock's defensive characteristics and strong cash flow generation provide support, but investors might want to wait for better entry points around the $235-240 range.

Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company is focused on improving the lives of people and animals around the world. It is engaged in the delivery of pharmaceuticals, healthcare products, and solutions. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.

Based on the provided data and analysis, here is the price prediction for COR stock by 2030:

COR stock is projected to reach $320-350 by 2030, driven by its strong competitive advantages in pharmaceutical distribution and healthcare solutions. The company's high capital turnover business model generating consistent cash flows and its strategic expansion into high-growth areas like specialty products and GLP-1 drugs support this growth trajectory.

Recent analyst actions reinforce this outlook, with Barclays initiating coverage with a $242 price target and Buy rating in January 2024, highlighting the company's robust business fundamentals.

COR has a total of 42000 employees.